Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:51 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
NCT02711137 · Incyte Corporation · PHASE1/PHASE2 · terminated · last registry update 2025-10-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study terminated due to safety issues.” | – | Registry record, Incyte Corporation |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PARP1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-20Also stopped (withdrawn): Massachusetts General Hospital, Telaglenastat + Talazoparib (NCT04824937)
- 2026-10-19Also stopped (terminated): Novartis Pharmaceuticals, Alpelisib + Olaparib (NCT04729387)
- 2026-10-06Results posted on the registry: Memorial Sloan Kettering Cancer Center, Talazoparib + Axitinib (NCT04337970)
- 2026-09-25Results posted on the registry: AstraZeneca, Neoadjuvant Olaparib monotherapy group + Neoadjuvant combination therapy with olaparib plus durvalumab (NCT05498155)
- 2026-09-25Results posted on the registry: CellCentric Ltd., CCS1477 + Abiraterone acetate (NCT03568656)
- 2026-09-24Results posted on the registry: Dana-Farber Cancer Institute, Niraparib + Dostarlimab (NCT04584255)
- 2026-09-22Also stopped (terminated): National Cancer Institute (NCI), Olaparib + Durvalumab (NCT04538378)
- 2026-09-21Also stopped (terminated): Massachusetts General Hospital, Niraparib + Osimertinib (NCT03891615)
- 2026-09-14Also stopped (terminated): Merck Sharp & Dohme LLC, Pembrolizumab + Olaparib (NCT04191135)
- 2026-09-01Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Paclitaxel + Olaparib (NCT04209686)
- 2026-08-26Results posted on the registry: University of Washington, Carboplatin + Docetaxel (NCT03442556)
- 2026-08-26Also stopped (terminated): University of Washington, Carboplatin + Docetaxel (NCT03442556)
- 2026-08-24Results posted on the registry: Memorial Sloan Kettering Cancer Center, Talazoparib + Temozolomide (NCT04019327)
- 2026-08-24Also stopped (terminated): Memorial Sloan Kettering Cancer Center, Talazoparib + Temozolomide (NCT04019327)
- 2026-08-20Results posted on the registry: Dana-Farber Cancer Institute, Olaparib + Ceralasertib (NCT04417062)
- 2026-08-17Results posted on the registry: University of Leicester, Rucaparib + Abemaciclib (NCT03654833)
- 2026-08-14Also stopped (terminated): National Cancer Institute (NCI), Olaparib (NCT05286827)
- 2026-08-14Results posted on the registry: Merck Sharp & Dohme LLC, Olaparib (NCT03742895)
- 2026-08-13Also stopped (terminated): National Cancer Institute (NCI), EP0057 + olaparib (NCT02769962)
- 2026-08-12Results posted on the registry: National Cancer Institute (NCI), Talazoparib + Temozolomide (NCT05142241)
- 2026-08-03Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Enfortumab Vedotin (NCT03869190)
- 2026-08-03Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Enfortumab Vedotin (NCT03869190)
- 2026-07-22Also stopped (terminated): Mayo Clinic, Abiraterone Acetate/Niraparib + Prednisone (NCT05689021)
- 2026-07-17Results posted on the registry: Memorial Sloan Kettering Cancer Center, Rucaparib + Nivolumab (NCT04624178)
- 2026-06-29Also stopped (terminated): University of Iowa, Niraparib + Dostarlimab (NCT04926324)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision